CYTOMED THERAPEUTICS LTD

GDTCNASDAQ

🏆 #4959 by market capEarnings Nov 13US Equity

$0.89▼ $0.03 (−3.89%)

🌙 After hours$0.81▼ 8.61%Regular close · extended-hours price shown

🔔

Track GDTC

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 3.9%

7d▼ 2.3%

14d▲ 10.2%

30d▼ 7.4%

ytd▼ 34.6%

1y▼ 54.2%

🏦Market Cap

$11M

Small Cap

📈Revenue Growth (YoY)

+359.3%

High Growth

📊Gross Margin

-20.5%

Thin

💵FCF Margin

-986.0%

Thin

⚖️P/S Ratio

22.5x

Expensive

Otter Score

Good

Trading Snapshot

Day Range: $0.88 – $0.90
52-Week Range: $0.68 – $3.68
Volume: $2.23B
Avg Volume: $1.89B
Shares Outstanding: 11.8M
Next Earnings: Nov 6, 2026

Fundamentals Snapshot

Annual Revenue: $319,201
Last Q Revenue: $167,945
P/E Ratio: -3.0
P/S Ratio: 22.5x
EPS (TTM): $-0.41
Dividend Yield: 0.00%
Dilution (1yr): +2.2%

Why Investors Own GDTC

✓High-growth profile — revenue up +47.2% YoY with expanding US Equity exposure.
✓Healthy economics — 50% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CYTOMED THERAPEUTICS LTD

GDTC

Financial Trends

Revenue

$319K▲ +359.3% YoY

Gross Margin

-277.7%▼ −468.5% YoY

Operating Income

−$5M▲ +44.4% YoY

Free Cash Flow

−$4M▲ +7.1% YoY

Shares Outstanding

11.8M▲ +2.2% YoY

Net Cash

$2M▼ −$3M YoY

StockOtter · stockotter.space

About CYTOMED THERAPEUTICS LTD

CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.

🦦